Scarica l'app Stockscreener
414.51
1.47%
-6.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$421.15
Aprire:
$419.31
Volume 24 ore:
572.47K
Relative Volume:
0.33
Capitalizzazione di mercato:
$106.37B
Reddito:
$11.39B
Utile/perdita netta:
$3.64B
Rapporto P/E:
29.63
EPS:
13.9904
Flusso di cassa netto:
$3.50B
1 W Prestazione:
+1.49%
1M Prestazione:
+4.66%
6M Prestazione:
-13.96%
1 anno Prestazione:
-11.33%
Intervallo 1D:
$414.28
$421.01
Intervallo di 1 settimana:
$400.74
$422.73
Portata 52W:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
414.87 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.13 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.26 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
802.39 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
334.81 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Recovering from injury, Boston Celtics star Jayson Tatum laces up for Vertex campaign - Medical Marketing and Media
Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025? - Yahoo Finance
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors - businesswire.com
Prime Capital Investment Advisors LLC Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $530.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Indicators - Markets Mojo
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Motley Fool
Vertex’s quest for a breakthrough in Type 1 diabetes - Pharma Voice
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
RBC Raises Price Target on Vertex Pharmaceuticals to $423 From $405, Keeps Sector Perform Rating - MarketScreener
Dohj LLC Purchases Shares of 857 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Smartest Growth Stock to Buy With $500 Right Now - Yahoo Finance
The 5 Most Powerful Women in Biopharma - BioSpace
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Stake Lifted by KLP Kapitalforvaltning AS - MarketBeat
Shell Asset Management Co. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
SteelPeak Wealth LLC Makes New $10.06 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Simplicity Wealth LLC Purchases 1,736 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals a Smart Investment After Recent FDA Approval for Sickle Cell Therapy? - Sahm
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd - businesswire.com
Former Vertex COO named chief executive at Dravet-focused biotech - The Business Journals
What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet? - Yahoo
Vertex Pharmaceuticals: Strong Growth Potential with Promising Product Launches and Robust Pipeline - TipRanks
Cullinan Associates Inc. Sells 1,100 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Will Vertex Pharmaceuticals Incorporated price bounce be sustainableJuly 2025 Momentum & AI Enhanced Execution Alerts - newser.com
Published on: 2025-10-06 04:49:48 - newser.com
DAVENPORT & Co LLC Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Global Assets Advisory LLC Sells 1,124 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
QRG Capital Management Inc. Raises Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals Incorporated (VX1) stock remains top ratedQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
Is Vertex Pharmaceuticals Incorporated reversing from oversold territoryWeekly Trade Report & Precise Swing Trade Entry Alerts - newser.com
Will Vertex Pharmaceuticals Incorporated (VX1) stock outperform value peersMarket Volume Report & Free High Accuracy Swing Entry Alerts - newser.com
Vertex Pharmaceuticals (VRTX) Highlights Pipeline Progress at BofA Global Healthcare Conference - MSN
Chart based exit strategy for Vertex Pharmaceuticals IncorporatedMarket Rally & Daily Stock Trend Watchlist - newser.com
News impact scoring models applied to Vertex Pharmaceuticals IncorporatedQuarterly Investment Review & Weekly Watchlist of Top Performers - newser.com
Boston Common Asset Management LLC Has $20.51 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Can Vertex Pharmaceuticals Incorporated stock resist sector downturnsTrade Entry Summary & Breakout Confirmation Trade Signals - newser.com
Strid Group LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals Incorporated (VX1) stock could outperform next year2025 Technical Overview & Reliable Breakout Forecasts - newser.com
Ascent Group LLC Sells 790 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
AMF Tjanstepension AB Increases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
J. Safra Sarasin Holding AG Has $1.34 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
NHS England to Offer Alyftrek for Cystic Fibrosis - respiratory-therapy.com
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' - Benzinga
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs? - Pharma Voice
Vertex Pharmaceuticals (VRTX): Assessing Valuation as Shares Hold Steady and Long-Term Prospects Remain Key - Yahoo Finance
Is Vertex Pharmaceuticals Incorporated (VX1) stock overpriced at current multiplesJuly 2025 Update & Free Long-Term Investment Growth Plans - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Greenwood Capital Associates LLC - MarketBeat
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
4.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):